ATAI Stock Summary and Trading Ideas (Ataibeckley | NASDAQ:ATAI)

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Ataibeckley trades on the NASDAQ stock market under the symbol ATAI.

As of January 9, 2026, ATAI stock price declined to $3.75 with 4,702,440 million shares trading.

ATAI has a beta of 0.86, meaning it tends to be less sensitive to market movements. ATAI has a correlation of 0.03 to the broad based SPY ETF.

ATAI has a market cap of $1.36 billion. This is considered a Small Cap stock.

Last quarter Ataibeckley reported $749,000 in Revenue and -$.28 earnings per share. This beat revenue expectation by $693,440 and missed earnings estimates by -$.16.

In the last 3 years, ATAI traded as high as $6.75 and as low as $1.03.

The top ETF exchange traded funds that ATAI belongs to (by Net Assets): ARKG, IBB, PSIL, NUSC, BBSC.

ATAI has outperformed the market in the last year with a return of +131.5%, while the SPY ETF gained +19.0%. However, in the most recent history, ATAI shares have underperformed the stock market with its stock returning -31.2% in the last 3 month period and -7.9% for the last 2 week period, while SPY has returned +3.7% and +0.5%, respectively.

ATAI support price is $3.80 and resistance is $4.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATAI shares will trade within this expected range on the day.